Navigation Links
Genaera Corporation Announces First Quarter Financial Results

PLYMOUTH MEETING, Pa., May 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced its financial results for the quarter ended March 31, 2008. The net loss for the quarter ended March 31, 2008 was $4.3 million, or $(0.24) per basic and diluted share, as compared to a net loss of $4.2 million, or $(0.24) per basic and diluted share, for the quarter ended March 31, 2007.

Genaera's research and development expenses for the quarter ended March 31, 2008 were $3.8 million compared to $3.5 million for the same period in 2007. The increase was due to increases in expenses related to the trodusquemine (MSI-1436) program for obesity and type 2 diabetes and a net increase in indirect expenses due to an increase in stock-based compensation related to stock options granted, partially offset by decreases in realignment costs and other indirect costs. These increases were partially offset by decreases in expenses related to the squalamine program for the treatment of wet age-related macular degeneration, the LOMUCIN(TM) program for the treatment of cystic fibrosis and the anti-IL9 antibody program.

Genaera's general and administrative expenses for the quarter ended March 31, 2008 were $2.2 million compared to $1.4 million for the same period in 2007. The increase was due to increases in stock-based compensation expense and an increase in legal fees.

The Company's cash, cash equivalents and short-term investments balance was $17.1 million at March 31, 2008.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a phase 1 trial in obesity. In addition, Genaera has a value- driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436) and the IL-9 antibody program. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates including trodusquemine (MSI-1436) and the IL-9 antibody program may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.




(In thousands, except per share data)

Three Months Ended

March 31,

2008 2007

Revenues $ 1,309 $ 207

Costs and expenses:

Research and development 3,838 3,470

General and administrative 2,185 1,432

6,023 4,902

Loss from operations (4,714) (4,695)

Interest income 176 367

Loss before income taxes (4,538) (4,328)

Income tax benefit 281 147

Net loss $(4,257) $(4,181)

Net loss per share --

basic and diluted $ (0.24) $(0.24)

Weighted average shares outstanding --

basic and diluted 17,463 17,443



(In thousands)

March 31, 2008 December 31, 2007

Cash, cash equivalents and short-term

investments $17,098 $20,900

Prepaid expenses and other current

assets 804 356

Fixed assets, net 344 374

Other assets 56 56

Total assets $18,302 $21,686

Current liabilities $2,499 $3,377

Other liabilities 63 70

Stockholders' equity 15,740 18,239

Total liabilities and stockholders'

equity $18,302 $21,686

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genaera Corporation Announces 2007 Financial Results
2. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera to Present at Biotech 2007 and BIO InvestorForum
5. Genaera Elects New Board Member and Announces Executive Appointments
6. EUSA Pharma Completes Acquisition Of Cytogen Corporation
7. Pharmos Corporation Reports 2008 First Quarter Results
8. Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008
9. Mac-Gray Corporation Announces First-Quarter 2008 Financial Results
10. MannKind Corporation Reports First Quarter Financial Results
11. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):